One shot to prevent cancer: new HPV vaccine tested in zambia

NCT ID NCT07256912

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of the CERVAVAC HPV vaccine works as well as a single dose of Gardasil in preventing HPV infection. About 1,266 girls, boys, and young women in Zambia will receive one shot of either vaccine. Researchers will check their immune response at 6, 12, and 24 months to see if the vaccines are equally effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
quadrivalent HPV vaccine (CERVAVAC or Gardasil)
What this could lead to
If successful, a single dose of CERVAVAC could offer a simpler, cheaper way to prevent cervical cancer in young people.
What could go wrong
This is a Phase 4 trial, but it only measures immune response, not actual cancer prevention. Results may not apply to other populations or HPV types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chipata and Matero First Level Hospitals

    Lusaka, Zambia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.